Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01621542 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of WT2725 in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01621542 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 64 participants.
The verdict
NCT01621542, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This clinical study is designed to evaluate the safety, immunogenicity and antitumor activity of WT2725. WT2725 will be administered to patients with advanced malignancies known to overexpress WT1
Interventions
- BIOLOGICAL WT2725
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2012-07-31 |
| Est. Completion | 2017-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01621542
The ClinicalTrials.gov registry entry for NCT01621542 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WT2725 is the first listed.
NCT01621542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01621542 about?
NCT01621542 is a clinical study titled "Clinical Study of WT2725 in Patients With Advanced Malignancies". This clinical study is designed to evaluate the safety, immunogenicity and antitumor activity of WT2725. WT2725 will be administered to patients with advanced malignancies known to overexpress WT1
What is the current status of trial NCT01621542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2012-07-31. Estimated completion is 2017-05-17.
What interventions are being tested in trial NCT01621542?
The interventions under investigation include: WT2725 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01621542?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.